146 related articles for article (PubMed ID: 9551900)
1. MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes.
Armstrong TD; Clements VK; Ostrand-Rosenberg S
J Immunol; 1998 Jan; 160(2):661-6. PubMed ID: 9551900
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway.
Rock KL; Clark K
J Immunol; 1996 May; 156(10):3721-6. PubMed ID: 8621907
[TBL] [Abstract][Full Text] [Related]
3. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
4. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
5. Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response.
Zhou G; Ding ZC; Fu J; Levitsky HI
J Immunol; 2011 Feb; 186(4):2148-55. PubMed ID: 21242518
[TBL] [Abstract][Full Text] [Related]
6. Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo.
Qi L; Rojas JM; Ostrand-Rosenberg S
J Immunol; 2000 Nov; 165(10):5451-61. PubMed ID: 11067897
[TBL] [Abstract][Full Text] [Related]
7. The dependence for leukocyte function-associated antigen-1/ICAM-1 interactions in T cell activation cannot be overcome by expression of high density TCR ligand.
Abraham C; Griffith J; Miller J
J Immunol; 1999 Apr; 162(8):4399-405. PubMed ID: 10201975
[TBL] [Abstract][Full Text] [Related]
8. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition.
Patel DM; Arnold PY; White GA; Nardella JP; Mannie MD
J Immunol; 1999 Nov; 163(10):5201-10. PubMed ID: 10553040
[TBL] [Abstract][Full Text] [Related]
9. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
Baskar S; Clements VK; Glimcher LH; Nabavi N; Ostrand-Rosenberg S
J Immunol; 1996 May; 156(10):3821-7. PubMed ID: 8621919
[TBL] [Abstract][Full Text] [Related]
10. BALB/c invariant chain mutant mice display relatively efficient maturation of CD4+ T cells in the periphery and secondary proliferative responses elicited upon peptide challenge.
Kenty G; Bikoff EK
J Immunol; 1999 Jul; 163(1):232-41. PubMed ID: 10384121
[TBL] [Abstract][Full Text] [Related]
11. I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice.
Noorchashm H; Lieu YK; Noorchashm N; Rostami SY; Greeley SA; Schlachterman A; Song HK; Noto LE; Jevnikar AM; Barker CF; Naji A
J Immunol; 1999 Jul; 163(2):743-50. PubMed ID: 10395666
[TBL] [Abstract][Full Text] [Related]
12. Rejection of mouse sarcoma cells after transfection of MHC class II genes.
Ostrand-Rosenberg S; Thakur A; Clements V
J Immunol; 1990 May; 144(10):4068-71. PubMed ID: 2332639
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo.
Xiang J; Moyana T
Cancer Gene Ther; 1998; 5(5):313-20. PubMed ID: 9824051
[TBL] [Abstract][Full Text] [Related]
14. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes.
Herkel J; Jagemann B; Wiegard C; Lazaro JF; Lueth S; Kanzler S; Blessing M; Schmitt E; Lohse AW
Hepatology; 2003 May; 37(5):1079-85. PubMed ID: 12717388
[TBL] [Abstract][Full Text] [Related]
15. CD4+ T cells mature in the absence of MHC class I and class II expression in Ly-6A.2 transgenic mice.
Henderson SC; Berezovskaya A; English A; Palliser D; Rock KL; Bamezai A
J Immunol; 1998 Jul; 161(1):175-82. PubMed ID: 9647222
[TBL] [Abstract][Full Text] [Related]
16. Unexpected reactivities of T cells selected by a single MHC-peptide ligand.
Singh N; Van Kaer L
J Immunol; 1999 Oct; 163(7):3583-91. PubMed ID: 10490950
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
[TBL] [Abstract][Full Text] [Related]
18. MHC class II-positive perivascular microglial cells mediate resistance to Cryptococcus neoformans brain infection.
Aguirre K; Miller S
Glia; 2002 Aug; 39(2):184-8. PubMed ID: 12112369
[TBL] [Abstract][Full Text] [Related]
19. Interaction of retinal pigmented epithelial cells and CD4 T cells leads to T-cell anergy.
Gregerson DS; Heuss ND; Lew KL; McPherson SW; Ferrington DA
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4654-63. PubMed ID: 17898289
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
